每周紫杉醇、卡铂和西妥昔单抗作为诱导化疗或头颈癌转移或复发的疗效和毒性，重点是老年人或体弱患者

Head & neck surgery Pub Date : 2022-04-30 DOI:10.1002/hed.27077

R. Forman, H. Deshpande, B. Burtness, A. Bhatia

{"title":"每周紫杉醇、卡铂和西妥昔单抗作为诱导化疗或头颈癌转移或复发的疗效和毒性，重点是老年人或体弱患者","authors":"R. Forman, H. Deshpande, B. Burtness, A. Bhatia","doi":"10.1002/hed.27077","DOIUrl":null,"url":null,"abstract":"Paclitaxel, carboplatin, and cetuximab (PCC) has shown promise as induction chemotherapy and in patients with metastatic/recurrent head and neck cancer (HNC). Given its tolerability, the regimen is used in frail and elderly patients.","PeriodicalId":75895,"journal":{"name":"Head & neck surgery","volume":"3 1","pages":"1777 - 1786"},"PeriodicalIF":0.0000,"publicationDate":"2022-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a focus on elderly or frail patients\",\"authors\":\"R. Forman, H. Deshpande, B. Burtness, A. Bhatia\",\"doi\":\"10.1002/hed.27077\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Paclitaxel, carboplatin, and cetuximab (PCC) has shown promise as induction chemotherapy and in patients with metastatic/recurrent head and neck cancer (HNC). Given its tolerability, the regimen is used in frail and elderly patients.\",\"PeriodicalId\":75895,\"journal\":{\"name\":\"Head & neck surgery\",\"volume\":\"3 1\",\"pages\":\"1777 - 1786\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-04-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Head & neck surgery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/hed.27077\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Head & neck surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/hed.27077","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 3

摘要

紫杉醇、卡铂和西妥昔单抗(PCC)在转移性/复发性头颈癌(HNC)患者中显示出诱导化疗的前景。鉴于其耐受性，该方案适用于体弱和老年患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a focus on elderly or frail patients

Paclitaxel, carboplatin, and cetuximab (PCC) has shown promise as induction chemotherapy and in patients with metastatic/recurrent head and neck cancer (HNC). Given its tolerability, the regimen is used in frail and elderly patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Head & neck surgery

自引率

0.00%

发文量